References: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for lipid modification

Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354(12):1264-72. https://www.ncbi.nlm.nih.gov/pubmed/16554528
Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med 2016;375(22):2144-53. https://www.ncbi.nlm.nih.gov/pubmed/27959767
Krychtiuk KA, Speidl WS. State-of-the-art lipid-lowering for secondary prevention - focus on drug therapy. e-Journal of Cardiology Practice. Sophia Antipolis, France: European Society of Cardiology; 2020. 19 (2) Accessed 9 Sep 2022. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/state-of-the-art-lipid-lowering-for-secondary-prevention-focus-on-drug-therapy
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017;376(18):1713-22. https://www.ncbi.nlm.nih.gov/pubmed/28304224